(Q38882332)

English

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells

scientific article published on 24 April 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

11

object named as

Michael Hallek

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

author name string

Elisa Göckeritz

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Susan Kerwien

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Michael Baumann

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Marion Wigger

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Verena Vondey

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Lars Neumann

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Thomas Landwehr

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Clemens M Wendtner

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Christian Klein

9

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Ningshu Liu

10

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Lukas P Frenzel

12

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Günter Krause

13

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

0 references

publication date

24 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

137

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

2234-2242

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Targeting pathological B cell receptor signalling in lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Synthesis and function of 3-phosphorylated inositol lipids

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

The phosphoinositide 3-kinase pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Targeting phosphoinositide 3-kinase: moving towards therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

The PI3K pathway as drug target in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

PI3K and cancer: lessons, challenges and opportunities

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Pharmacologic interception in T-cell leukemia 1A associated pathways as a treatment rationale for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Targeting nonclassical oncogenes for therapy in T-ALL.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.29579

21 January 2018

Identifiers

10.1002/IJC.29579

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38882332&oldid=1793432614"